Transcatheter aortic valve implantation in patients with bicuspid aortic valve: A patient level multi-center analysis.

Yousef A, Simard T, Webb J, Rodés-Cabau J, Costopoulos C, Kochman J, Hernández-Garcia JM, Chiam PT, Welsh RC, Wijeysundera HC, García E, Ribeiro HB, Latib A, Huczek Z, Shanks M, Testa L, Farkouh ME, Dvir D,Velianou JL, Lam BK, Pourdjabbar A, Glover C, Hibbert B, Labinaz M.

Abstract

OBJECTIVE:

We sought to evaluate the safety and efficacy of transcatheter aortic valve implantation (TAVI) in patients with bicuspid aortic valve (BiAV).

BACKGROUND:

BiAV remains a relative contraindication to TAVI resulting in exclusion from TAVI trials and thus limiting data on the clinical performance of transcatheter valves in these patients.

METHODOLOGY:

We conducted an international patient level multicenter analysis on outcomes in patients with BiAV undergoing TAVI. The primary outcome of the study was the combined early safety endpoint–a composite of 30 day mortality, stroke, life-threatening bleeding, acute kidney injury, coronary artery obstruction, major vascular complication and valve related dysfunction. Secondary endpoints included the individual components of the primary endpoint as well as post-TAVI paravalvular leak (PVL), rehospitalization, new pacemaker insertion and device success rates at 30 days and 1 year.

RESULTS:

A total of 108 patients with BiAV were identified in 21 centers in Canada, Spain, Italy, Poland and Singapore who underwent TAVI between January 2005 and March 2014. The composite primary outcome occurred in one quarter of patients (26.9%)–mainly driven by re-intervention for valve malposition (9.3%). The 30-day and 1 year mortality rates were 8.3% and 16.9% respectively with AR ≥ 3+ occurring in 9.6% of patients. Device success was achieved in 85.2% of cases with pacemaker insertion in 19.4%. While PVL was not associated with an increased risk of 30 day or 1 year mortality–Type I BiAV anatomy with left and right cusp fusion had significantly better outcomes than other valve variants.

CONCLUSION:

In selected patients with BiAV and severe aortic stenosis, TAVI appears both safe and feasible with acceptable clinical outcomes. Clinical studies of TAVI in this patient population are warranted.

Diagram showing the components and placement of a Left Ventricular Assist Device (LVAD)

What Is an Artificial Heart Pump (LVAD) and Who Needs One?

For patients with advanced heart failure, medications alone may no longer be enough to help the heart pump blood effectively. A Left Ventricular Assist Device (LVAD), often referred to as an artificial heart pump, can help improve blood flow, relieve symptoms, and enhance quality of life. Learn how LVADs work, who may benefit from them, and what to expect before, during and after implantation.

Middle-aged Asian man clutching his chest, appearing to experience chest pain or symptoms of cardiac arrest.

Can Healthy Individuals Get Cardiac Arrest?

Even seemingly healthy individuals without known heart conditions can experience cardiac arrest. Recognising risk factors and adopting a heart-healthy lifestyle, including regular exercise, a balanced diet, avoiding smoking, limiting alcohol intake, managing stress and going for health screening regularly, can potentially reduce the risk.

Leaky tricuspid valve (tricuspid regurgitation) showing backward blood flow from the right ventricle into the right atrium

Minimally Invasive Treatment Options for Leaky Tricuspid Valve

A leaky tricuspid valve, also known as tricuspid regurgitation, is a heart valve condition that can cause swelling, breathlessness, fatigue, and worsening heart failure if left untreated. While open-heart surgery was once the only definitive treatment, advances in heart valve technology now allow selected patients to be treated using minimally invasive catheter-based procedures, including tricuspid transcatheter edge-to-edge repair, transcatheter tricuspid valve replacement, and caval valve implantation.

the connection between sleep problems and heart failure

The Hidden Connection between Sleep Problems and Heart Failure

Sleep problems are common among people with heart failure, and research shows the relationship goes both ways. Conditions such as obstructive sleep apnoea (OSA) and insomnia can worsen heart failure symptoms, while heart failure itself often leads to disturbed or poor-quality sleep. Recognising this two-way connection is an important step toward better symptom control and long-term heart health.

Transcatheter aortic valve implantation in patients with bicuspid aortic valve: A patient level multi-center analysis.